Related Experiment Videos
Increased tumor cell proliferation in murine tumors with decreasing dosage of wild-type p53
S D Tyner1, J Choi, R Laucirica
1Division of Molecular Virology, Baylor College of Medicine, Houston, Texas 77030, USA.
Abstract:
A number of transgenic animal model systems have addressed the mechanistic role of p53 loss in tumor progression. However, many of these tumor models have analyzed p53 function in the context of other transgenes expressing activated oncogenes or defective tumor suppressor genes generated by gene targeting. To examine the role of p53 loss independent of other exogenous oncogenic influences, we analyzed some of the biological aspects of tumor formation and progression in p53-knockout mice containing a null germline p53 allele. We analyzed tumors from p53-/-, p53+/-, and p53+/+ littermates. Some of the p53+/- tumors had lost the remaining p53 allele (p53+/- loss of heterozygosity), whereas others retained the allele (p53+/-). In this report, we show that loss or absence of p53 conferred a tumor growth advantage by increasing the rate of cellular proliferation in a p53 dosage-dependent manner. The apoptotic levels in tumor tissue were found to be modest and not significantly dependent on p53 status. These results contrast with those from some other p53-deficient tumor models, in which p53 loss was associated with more rapid tumor progression through abrogated apoptosis. Finally, as p53 has been shown to regulate certain angiogenic factors, we examined the levels of angiogenesis in p53-containing and p53-deficient tumors. We found no p53-dependent differences in the levels of tumor angiogenesis measured by intratumoral microvessel density.
Insights
Loss of the tumor suppressor p53 (also known as TP53) accelerates tumor growth by increasing cell proliferation in a dosage-dependent manner. This study found no significant p53-dependent changes in apoptosis or angiogenesis in p53-knockout mouse models.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The tumor suppressor p53 (TP53) plays a critical role in preventing cancer.
- Transgenic animal models are crucial for studying p53's function in tumor progression.
- Previous models often confound p53's role with other genetic alterations.
Purpose of the Study:
- To investigate the role of p53 loss in tumor formation and progression independently of other oncogenic influences.
- To analyze the impact of p53 dosage on tumor growth, proliferation, and apoptosis.
- To assess the relationship between p53 status and tumor angiogenesis.
Main Methods:
- Utilized p53-knockout (p53-/-), heterozygous (p53+/-), and wild-type (p53+/+) littermate mice.
- Analyzed tumors for p53 status, including loss of heterozygosity in p53+/- mice.
- Quantified cellular proliferation rates, apoptotic levels, and tumor angiogenesis (microvessel density).
Main Results:
- Loss or absence of p53 significantly increased tumor growth rate by enhancing cellular proliferation in a p53 dosage-dependent manner.
- Apoptotic levels in tumors were modest and not significantly influenced by p53 status.
- No significant differences in tumor angiogenesis, measured by microvessel density, were observed based on p53 status.
Conclusions:
- p53 deficiency confers a tumor growth advantage primarily through increased proliferation, independent of significant changes in apoptosis or angiogenesis.
- These findings highlight the dosage-dependent impact of p53 on tumor progression.
- The study provides insights into p53's role in cancer, distinct from models involving other genetic mutations.